An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE
An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE is a PHASE1 clinical asset sponsored by Miltenyi Biomedicine GmbH in SLE - Systemic Lupus Erythematosus. SEO and diligence focus: MB-CART19.1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: SLE - Systemic Lupus Erythematosus
Modality: protein therapy
Target: MB-CART19.1
Sponsor: Miltenyi Biomedicine GmbH
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: MB-CART19.1
View original source fields
Condition raw: SLE - Systemic Lupus Erythematosus
Condition normalized: SLE - Systemic Lupus Erythematosus
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: MB-CART19.1
Target normalized: MB-CART19.1